|
1
|
Galectins and their ligands: amplifiers, silencers or tuners of the inflammatory response?
|
Trends Immunol
|
2002
|
2.19
|
|
2
|
90K (Mac-2 BP) and galectins in tumor progression and metastasis.
|
Glycoconj J
|
2004
|
1.33
|
|
3
|
Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts.
|
Cancer Lett
|
2008
|
1.00
|
|
4
|
Synthetic inhibitors of galectin-1 and -3 selectively modulate homotypic cell aggregation and tumor cell apoptosis.
|
Anticancer Res
|
2009
|
0.96
|
|
5
|
Changes of topoisomerase IIalpha expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival.
|
Clin Cancer Res
|
2006
|
0.93
|
|
6
|
LGALS3BP, lectin galactoside-binding soluble 3 binding protein, induces vascular endothelial growth factor in human breast cancer cells and promotes angiogenesis.
|
J Mol Med (Berl)
|
2012
|
0.90
|
|
7
|
Molecular mechanisms of endocrine resistance and their implication in the therapy of breast cancer.
|
Biochim Biophys Acta
|
2008
|
0.89
|
|
8
|
Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies.
|
Cancers (Basel)
|
2013
|
0.89
|
|
9
|
Meta-analysis of phase III trials of docetaxel alone or in combination with chemotherapy in metastatic breast cancer.
|
J Cancer Res Clin Oncol
|
2011
|
0.88
|
|
10
|
Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study.
|
Breast Cancer Res Treat
|
2014
|
0.88
|
|
11
|
An epigenetic approach to pancreatic cancer treatment: the prospective role of histone deacetylase inhibitors.
|
Curr Cancer Drug Targets
|
2012
|
0.86
|
|
12
|
Triplet chemotherapy in patients with metastatic colorectal cancer: toward the best way to safely administer a highly active regimen in clinical practice.
|
Clin Colorectal Cancer
|
2012
|
0.84
|
|
13
|
Lack of expression of galectin-3 is associated with a poor outcome in node-negative patients with laryngeal squamous-cell carcinoma.
|
J Clin Oncol
|
2002
|
0.84
|
|
14
|
Long-term outcome of neoadjuvant systemic therapy for locally advanced breast cancer in routine clinical practice.
|
J Cancer Res Clin Oncol
|
2012
|
0.82
|
|
15
|
High expression of 90K (Mac-2 BP) is associated with poor survival in node-negative breast cancer patients not receiving adjuvant systemic therapies.
|
Int J Cancer
|
2009
|
0.82
|
|
16
|
Tumor-derived microvesicles: the metastasomes.
|
Med Hypotheses
|
2012
|
0.81
|
|
17
|
Effectiveness and response predictive factors of erlotinib in a non-small cell lung cancer unselected European population previously treated: a retrospective, observational, multicentric study.
|
J Oncol Pharm Pract
|
2012
|
0.78
|
|
18
|
Inhibition of tumor growth and angiogenesis by SP-2, an anti-lectin, galactoside-binding soluble 3 binding protein (LGALS3BP) antibody.
|
Mol Cancer Ther
|
2014
|
0.78
|
|
19
|
Chemotherapy-induced nausea and vomiting in Italian cancer centers: results of CINVDAY, a prospective, multicenter study.
|
Tumori
|
2015
|
0.77
|
|
20
|
Expression of the 90K tumor-associated protein in benign and malignant melanocytic lesions.
|
J Invest Dermatol
|
2002
|
0.77
|
|
21
|
Breast cancer follow-up strategies in randomized phase III adjuvant clinical trials: a systematic review.
|
J Exp Clin Cancer Res
|
2013
|
0.76
|
|
22
|
Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer.
|
Ann Surg Oncol
|
2014
|
0.76
|